Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching

doi:10.4251/wjgo.v14.i8.1510

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5063)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-6) series.

Item

Count

PDF

200

WORD

HTML

2261

Figures (1-2)

227

Tables (1-6)

236

Sum=2981

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

255

Download

696

Sum=951

Publishing Process of This Article

Item

Count

Browse

310

Download

821

Sum=1131

Aug 15, 2022 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1510-1527
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1510

Full Size Figure Download Figure

Figure 2 Kaplan-Meier curves. A: Median overall survival in hepatocellular carcinoma (HCC) patients receiving regorafenib (REG) or cabozantinib (CBZ) (entire cohort n = 86); B: Median progression-free survival in HCC patients receiving REG vs CBZ as second-line therapy: matching-adjusted indirect comparison study; C: Median progression-free survival in HCC patients receiving second- or third-line CBZ. HCC: Hepatocellular carcinoma; REG: Regorafenib; CBZ: Cabozantinib.

Citation: Adhoute X, De Matharel M, Mineur L, Pénaranda G, Ouizeman D, Toullec C, Tran A, Castellani P, Rollet A, Oules V, Perrier H, Si Ahmed SN, Bourliere M, Anty R. Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching. World J Gastrointest Oncol 2022; 14(8): 1510-1527
URL: https://www.wjgnet.com/1948-5204/full/v14/i8/1510.htm
DOI: https://dx.doi.org/10.4251/wjgo.v14.i8.1510